MIR96 and hearing loss disorder: These findings suggest that the combination of AAV-U1A-SpCas9-polyA/AAV-sgmiR96-master can effectively target each of the three known human MIR96 mutations and holds promise for treating dominant hearing loss caused by MIR96-related mutations.